Key Points
- Insider purchase: Director Joseph Jr. Wilkins bought 370 shares on Nov. 26 at $27.95 for $10,341.50, raising his holding to 11,876 shares (a 3.22% increase).
- Earnings beat and guidance: QuidelOrtho reported Q (Nov 5) EPS of $0.80 vs. $0.51 expected with revenue $699.9M, and set FY2025 guidance of $2.00–$2.15 (analysts average ~2.3 EPS).
- Market and sentiment: Shares are down ~3.2% and trade near $26.48 (52-week range $19.50–$49.45), the company has a $1.8B market cap, and analysts’ consensus rating is "Reduce" with a $38.20 target.
QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) Director Joseph Jr. Wilkins bought 370 shares of QuidelOrtho stock in a transaction dated Wednesday, November 26th. The stock was purchased at an average price of $27.95 per share, with a total value of $10,341.50. Following the completion of the purchase, the director owned 11,876 shares in the company, valued at $331,934.20. This trade represents a 3.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
QuidelOrtho Stock Down 3.2%
QDEL stock opened at $26.48 on Tuesday. The stock's 50 day simple moving average is $26.58 and its 200 day simple moving average is $27.65. QuidelOrtho Corporation has a fifty-two week low of $19.50 and a fifty-two week high of $49.45. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 1.12. The company has a market cap of $1.80 billion, a P/E ratio of -4.05 and a beta of 0.35.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.29. The firm had revenue of $699.90 million during the quarter, compared to analysts' expectations of $667.45 million. QuidelOrtho had a positive return on equity of 5.29% and a negative net margin of 16.10%.The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.85 earnings per share. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. On average, research analysts expect that QuidelOrtho Corporation will post 2.3 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have commented on QDEL shares. UBS Group boosted their price target on shares of QuidelOrtho from $26.00 to $31.00 and gave the company a "neutral" rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. reduced their price objective on shares of QuidelOrtho from $26.00 to $22.00 and set an "underweight" rating for the company in a report on Friday, November 7th. Weiss Ratings restated a "sell (e+)" rating on shares of QuidelOrtho in a report on Wednesday, October 8th. Zacks Research cut shares of QuidelOrtho from a "hold" rating to a "strong sell" rating in a research report on Monday, October 13th. Finally, Citigroup reissued a "neutral" rating and set a $33.00 price objective (down from $40.00) on shares of QuidelOrtho in a report on Tuesday, October 7th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Reduce" and a consensus price target of $38.20.
Read Our Latest Report on QDEL
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in QDEL. T. Rowe Price Investment Management Inc. boosted its holdings in QuidelOrtho by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 11,447,188 shares of the company's stock worth $400,309,000 after purchasing an additional 208,362 shares during the last quarter. Invesco Ltd. lifted its position in shares of QuidelOrtho by 10.6% during the 1st quarter. Invesco Ltd. now owns 3,813,833 shares of the company's stock worth $133,370,000 after buying an additional 366,387 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of QuidelOrtho by 14.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company's stock worth $84,208,000 after buying an additional 350,636 shares during the last quarter. State Street Corp grew its holdings in shares of QuidelOrtho by 23.3% in the second quarter. State Street Corp now owns 2,700,940 shares of the company's stock valued at $77,841,000 after acquiring an additional 510,291 shares in the last quarter. Finally, Newtyn Management LLC increased its position in shares of QuidelOrtho by 58.3% during the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company's stock valued at $79,515,000 after acquiring an additional 994,332 shares during the last quarter. 99.00% of the stock is owned by institutional investors.
QuidelOrtho Company Profile
(
Get Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
